



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

12 April 2016  
EMA/264456/2016  
Procedure Management & Committees Support Division  
Scientific Committee Support Department

## Scientific recommendation on classification of advanced therapy medicinal products

Article 17 – Regulation (EC) No 1394/2007

**Disclaimer:** This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency

### **Brief description (or name where available) of the active substance(s)**

Bone marrow-derived autologous non-hematopoietic stem cells

### **Brief description of the finished product**

Bone marrow-derived autologous non-hematopoietic stem cells suspended in PBS/EDTA buffer enriched with 0.5% human serum albumin

### **Proposed indications**

Treatment of type II diabetes

### **EMA/CAT conclusion**

The committee adopted on 21<sup>st</sup> December 2015 the following scientific recommendations.

On the basis that the product:

- consists of engineered cells that are not intended to be used for the same essential function or functions in the recipient as in the donor



- is administered to human beings with a view to treating a disease through the metabolic action of its cells or tissues

the EMA/CAT considers that the product falls within the definition of a somatic cell therapy medicinal product.